Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States

被引：0
|
作者：
Mickaël Hiligsmann
Stuart S. Silverman
Andrea J. Singer
Leny Pearman
Jake Mathew
Yamei Wang
John Caminis
Jean-Yves Reginster
机构：
[1] CAPHRI Care and Public Health Research Institute,Department of Health Services Research
[2] Maastricht University,Division of Public Health, Epidemiology and Health Economics
[3] Cedars-Sinai Medical Center,Chair for Biomarkers of Chronic Diseases, College of Science
[4] Los Angeles and the OMC Clinical Research Center,undefined
[5] MedStar Georgetown University Hospital and Georgetown University Medical Center,undefined
[6] Radius Health,undefined
[7] Inc.,undefined
[8] University of Liège,undefined
[9] King Saud University,undefined
来源：
PharmacoEconomics | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：819 / 830
页数：11
相关论文
共 50 条
  • [21] Cost-Effectiveness of Frequent HIV Testing of High-Risk Populations in the United States
    Hutchinson, Angela B.
    Farnham, Paul G.
    Sansom, Stephanie L.
    Yaylali, Emine
    Mermin, Jonathan H.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 71 (03) : 323 - 330
  • [22] COST-EFFECTIVENESS OF CEMENT AUGMENTATION FOR THE FIXATION OF UNSTABLE TROCHANTERIC FRACTURES IN THE UNITED STATES
    Joeris, A.
    Kabiri, M.
    Galvain, T.
    Vanderkarr, M.
    Holy, C.
    Quintana Plaza, J.
    Schneller, J.
    Kammerlander, C.
    VALUE IN HEALTH, 2022, 25 (07) : S354 - S354
  • [23] COST-EFFECTIVENESS ANALYSIS OF ALENDRONATE THERAPY FOR SECONDARY PREVENTION OF OSTEOPOROTIC FRACTURES
    Moriwaki, K.
    Komaba, H.
    Noto, S.
    Yanagisawa, S.
    Takiguchi, T.
    Toujo, T.
    Inoue, H.
    Fukagawa, M.
    Takahashi, H. E.
    VALUE IN HEALTH, 2013, 16 (07) : A571 - A571
  • [24] The cost-effectiveness of parathyroid hormone and alendronate in high-risk osteoporotic women.
    Liu, H
    Michaud, K
    Nayak, S
    Karpf, DB
    Owens, DK
    Garber, AM
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S409 - S409
  • [25] The cost-effectiveness of parathyroid hormone and alendronate in high-risk osteoporotic women.
    Michaud, K
    Liu, H
    Nayak, S
    Owens, DK
    Garber, AM
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S266 - S266
  • [26] Cost-effectiveness analysis in the United States - Reply
    Pearson, SD
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (23): : 2722 - 2723
  • [27] Update on the cost-effectiveness of contraceptives in the United States
    Trussell, James
    Sinai, Irit
    CONTRACEPTION, 2010, 82 (04) : 391 - 392
  • [28] Cost-Effectiveness of Hormone Therapy in the United States
    Lekander, Ingrid
    Borgstrom, Fredrik
    Strom, Oskar
    Zethraeus, Niklas
    Kanis, John A.
    JOURNAL OF WOMENS HEALTH, 2009, 18 (10) : 1669 - 1677
  • [29] The cost-effectiveness of alendronate in the management of osteoporosis
    Kanis, John A.
    Adams, Judith
    Borgstrom, Fred
    Cooper, Cyrus
    Jonsson, Bengt
    Preedy, Danielle
    Selby, Peter
    Compston, Juliet
    BONE, 2008, 42 (01) : 4 - 15
  • [30] COST-EFFECTIVENESS OF ABALOPARATIDE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Hiligsmann, M.
    Williams, S. A.
    Fitzpatrick, L. A.
    Reginster, J. -Y.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S50 - S51
12345